Quarterly Results
VRNA Earnings Forecast
Looking ahead, VRNA remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 115.84M and an EPS of 0.17.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q3 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in VRNA long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: GBP
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how VRNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VRNA sees a -3.07% change in stock price 10 days leading up to the earnings, and a -4.83% change 10 days following the report. On the earnings day itself, the stock moves by +2.46%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -1.56% on the day following the earnings release and then changed by -7.71% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of VRNA's latest earnings report for FY2025Q1?
VRNA reported its FY2025Q1 earnings on 2025-04-29, showcasing a revenue of 76.34M against an estimate of 55.46M, resulting in a 37.66% surprise. The EPS was 0.27, surpassing the expected -0.22 by 222.73% . The stock experienced a 6.37% price change on the earnings day and a 5.67% change over the next five days, reflecting market reactions to the results.
How did VRNA's stock price react after the FY2025Q1 earnings release?
Following VRNA's FY2025Q1 earnings announcement on 2025-04-29, the stock price moved by 6.37% on the day of the release. Over the subsequent five days, it saw a 5.67% change. Historically, VRNA's stock price tends to shift by an average of -3.07% in the 10 days leading up to earnings and -4.83% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for VRNA for 2025/Q3?
For 2025/Q3, analysts estimate VRNA’s annual revenue to reach 115.84M, while the EPS is projected at 0.17. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.
How does VRNA's stock price correlate with earnings forecast revisions?
The correlation between VRNA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from VRNA's next earnings report?
Based on historical trends, VRNA's stock price typically moves by -3.07% in the 10 days before its earnings and -4.83% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of 0.17 and revenue of 115.84M.
What is the sentiment in Verona Pharma PLC (VRNA) Q1 2025 Earnings Call Summary?
The earnings call presents a mixed outlook. The launch of Ohtuvayre is successful, contributing to increased net product sales and positive early adoption metrics. However, the company reported significant losses and avoided providing specific future guidance, which could concern investors. The cash position is strong, but reliance on debt facilities poses potential risks. The lack of clear guidance and management's evasive responses during the Q&A may lead to uncertainty. Given the small market cap, the stock may experience volatility, but overall, the sentiment remains neutral due to the balance of positives and negatives.
